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ABSTRACT
Introduction: Data suggesting that cystatin C levels are linked to obesity, apart from renal pathology, are 
conflicting. The aim of the study was to explore the potential association between serum cystatin C levels, 
anthropometric, and cardiometabolic parameters in healthy middle-aged adults.
Methods: A total of 132 participants (mean age 56.2 ± 6.73 years, 69% females) were included in 
this cross-sectional study. Anthropometric and biochemical parameters, as well as blood pressure, were 
obtained.
Results: Obese participants displayed higher cystatin C levels than normal-weight participants (p < 0.001). 
Multiple linear regression analysis revealed that waist circumference (WC) (Beta = 0.376, p < 0.001) and 
estimated glomerular filtration rate (Beta = -0.484, p < 0.001) were independently associated with cysta-
tin C levels (R2 = 0.447; p < 0.001).
Conclusions: Cystatin C is associated with abdominal obesity independent of renal function. Its relation-
ship with changes in other target organs should be determined.
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INTRODUCTION
When first introduced, it was thought that serum 
cystatin C level was not influenced by pathologies 
other than renal disease (1). However, this assump-
tion has been questioned recently, since some studies ???????????????????????????????????????????????? © 2016 Milovan Jovanovic et al.; licensee University of Sarajevo - Faculty of Health Studies. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original work is properly 
cited.
have shown that serum cystatin C concentration is 
influenced by some other factors (2).
A recent discovery that cystatin C is expressed in 
human adipose tissue (3) has questioned its role in 
estimating glomerular filtration rate in obese indi-
viduals. Several previous studies have reported higher 
serum cystatin C levels in obese participants than in 
normal-weight subjects (3,4), and a significant pos-
itive correlation between cystatin C and anthropo-
metric indices was observed (5-7). Cystatin C was 
also shown to be a reliable marker for metabolic 
syndrome (8). Moreover, a recent study reported 
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that increased cystatin C values are associated with 
increased risk of cardiovascular morbidity, even in 
severely obese pediatric population (9).
However, these data were not supported by 
sufficient evidence, both in children (10-12) 
and adults (13-15), thus indicating that cystatin C 
is not affected by body fat distribution.
Consequently, it is still questionable whether obesity 
contributes to higher cystatin C levels. Moreover, 
data regarding the association between cystatin C 
level and obesity-related co-morbidities, compris-
ing insulin resistance, inflammation, dyslipidemia 
and hypertension, are not well elucidated, taking 
into account that obesity is an independent risk 
factor for diabetes mellitus (DM), cardiovascular 
disease (CVD), and chronic kidney disease (CKD). 
Therefore, the purpose of the current study was to 
determine serum cystatin C levels and to examine 
its potential associations with anthropometric and 




The study enrolled a total of 132 middle-aged adults 
(mean age 56.2 ± 6.73  years, 69% females) who 
volunteered to participate in the examination. The 
participants were recruited in the Primary Health 
Care Center in Podgorica, Montenegro during their 
regular check-up, in a period from March 2013 to 
October 2013. All the participants completed a 
questionnaire including demographic characteris-
tics, somatic illnesses, smoking history, and current 
medication use. Medical history and clinical exam-
inations were carried out on the same day.
The inclusion criteria were creatinine-based esti-
mated glomerular filtration rate (eGFR) ≥ 60 mL/
min/1.73 m² [calculated using the Chronic Kidney 
Disease Epidemiology Collaboration Equation 
(CKD-EPI)], and normoalbuminuria [urinary albu-
min excretion (UAE) < 30 mg/24 h], non-smokers, 
without signs and symptoms of acute inflammatory 
disease, urinary infection, CVD, with no history or 
the presence of malignancy, hypo-  and hyperthy-
roidism, as well as those who did not use any med-
ications in the previous 6  months. The inclusion 
criterion was also fasting glucose < 7.0 mmol/L. 
In addition, all participants with fasting glucose 
≥ 5.6 mmol/L, but ≤ 6.9 mmol/L, underwent a two-
hour oral glucose tolerance test (OGTT) with 75 g 
anhydrous glucose dissolved in 250  mL of water 
in order to exclude DM. Participants with 2-hour 
postload glucose ≥ 11.1 mmol/L were excluded from 
the study (16). Participants who had DM (fasting 
glucose ≥ 7.0 mmol/L or 2-hour postload glucose 
≥ 11.1 mmol/L), renal dysfunction (creatinine-based 
eGFR < 60 mL/min/1.73 m²), UAE ≥ 30 mg/24 h, 
type 1 DM, morbid obesity (body mass index [BMI] 
> 40  kg/m2), hepatic dysfunction, cardiovascular 
disorders, and high sensitivity C-reactive protein 
(hsCRP) > 10  mg/L (17) were excluded from the 
study, as well as those who used anti-inflammatory, 
lipid-lowering, hypoglycemic, antihypertensive, or 
any other medications that might influence the asso-
ciation between cystatin C and other variables.
The participants were instructed not to perform any 
vigorous physical activity the day before the blood 
samples were taken. All the participants provided 
written informed consent. The study protocol was 
approved by the Ethical Committee of Primary 
Health Care Center in Podgorica, Montenegro, and 
the research was carried out in compliance with the 
Declaration of Helsinki.
Anthropometric measurements
Basic anthropometric measurements: Body height 
(cm), body weight (kg), and waist circumference 
(WC) (cm) were obtained in the morning. Weight 
was measured to the nearest 0.1  kg on a balance 
beam scale, with the subjects barefoot and with light 
clothes. Height was measured to the nearest 0.1 cm 
using a wall-mounted stadiometer, without shoes. 
WC was measured with a non-stretchable tape, over 
the unclothed abdomen at the midpoint between 
the lowest rib and the iliac crest. The tape was paral-
lel to the floor and did not compress the skin. BMI 
was calculated as weight in kilograms divided by 
height in meters squared (kg/m2).
Blood pressure (BP) was measured with a sphyg-
momanometer after the subject had been seated for 
15  minutes. Average of three measurements taken 
on the right arm was recorded. All measurements 
were taken by the same trained evaluator.
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The participants were divided into two groups: Nor-
mal weight (n = 53; 18.5 < BMI < 25 kg/m2, WC 
< 80 cm and WC < 94 cm for females and males, 
respectively) and overweight/obese (n = 79; 25 ≤ 
BMI < 40 kg/m2, WC ≥ 80 cm and WC ≥ 94 cm 
for females and males, respectively). Although our 
obese population consisted of slightly obese (over-
weight, n = 45; 25 ≤ BMI < 30 kg/m2) and mod-
erately obese (n = 34; 30 ≤ BMI < 40 kg/m2), for 
simplicity reasons, we referred to them as the obese 
participants.
Biochemical measurements
The blood samples were taken between 7-9 hours 
a.m., 12-14 hours after an overnight fast. Samples 
were allowed to clot for 30 minutes and then cen-
trifuged at 3000  rpm for 10  minutes. Serum lev-
els of glucose, creatinine, total cholesterol (TC), 
high density lipoprotein cholesterol (HDL-C), low 
density lipoprotein cholesterol (LDL-C), and tri-
glycerides (TG) were measured spectrophotomet-
rically (Roche Cobas 400, Mannheim, Germany), 
using standardized enzymatic procedures. Urinary 
albumin excretion was measured with an immuno-
turbidimetric assay (Roche Cobas 400, Mannheim, 
Germany). Cystatin C and hsCRP levels were 
determined using an immunonephelometric assay 
(Behring Nephelometer Analyzer, BN II, Marburg, 
Germany). Insulin was measured by chemilumi-
nescent immunometric assay (Immulite 2000, 
Siemens, Munich, Germany). Homeostasis model 
assessment of insulin resistance (HOMA-IR) was 
calculated using the formula HOMA-IR = Fasting 
glucose (mmol/L) x fasting insulin (µIU/L)/22.5. 
Glomerular filtration rate was estimated using cre-
atinine in the CKD-EPI (18).
Statistical analysis
Statistical analysis was performed using SPSS sta-
tistical package (version 15.0 for Windows, SPSS, 
Chicago, IL, USA). Data are presented as mean ± 
standard deviation or median (interquartile range), 
or counts and percentages. Differences between 
groups were evaluated with the Student’s t test for 
normally or Mann-Whitney test for non-normally 
distributed parameters, and χ² test was used for 
categorical variables. A  correlation analysis was 
performed to determine the relationships between 
cystatin C levels and other variables. Multiple linear 
regression analysis was performed to identify inde-
pendent factors affecting cystatin C and to estimate 
the final predictors of its variability. A  p value of 
<0.05 was considered as statistically significant.
RESULTS
Table  1 shows the general clinical and biochemi-
cal characteristics of the study participants divided 
into normal weight and obese groups. As expected, 
compared with the normal-weight, the obese partic-
ipants had higher fasting glucose (p = 0.006), fasting 
insulin and HOMA-IR (p < 0.001, respectively), TG 
(p = 0.015), systolic blood pressure (SBP), diastolic 
blood pressure (DBP) and hsCRP levels (p < 0.001, 
respectively), but lower HDL-C levels (p < 0.001). 
Moreover, the obese participants displayed higher 
serum cystatin C level (p < 0.001). No significant 
difference was found with respect to the age, sex, 
TC, and LDL-C levels between these two groups. 
Furthermore, there was no difference in the serum 
creatinine, eGFR, and UAE levels.
The relationships between cystatin C and clinical and 
biochemical characteristics are presented in Table 2. 
As shown, the serum cystatin C level correlated 
positively with the age (p = 0.021), BMI and WC 
(p < 0.001, respectively), fasting glucose (p = 0.002), 
TG (p = 0.028), fasting insulin, HOMA-IR, creat-
inine, SBP, DBP, hsCRP (p < 0.001, respectively), 
and negatively with HDL-C (p = 0.034) and eGFR 
(p < 0.001) in all participants. No significant asso-
ciation between the serum cystatin C level and TC, 
LDL-C and UAE was found (Table 2).
In order to find out if the examined anthropomet-
ric parameters were significantly associated with the 
serum cystatin C level independently of renal func-
tion, linear regression models were performed in the 
whole group of participants (Table 3). Due to stron-
ger association between WC and cystatin C com-
pared to the association between BMI and cystatin 
C, the associations of WC (rather than BMI) and 
eGFR with cystatin C were analyzed independently. 
Significant positive correlations between cystatin C 
and WC were observed even after adjustment for age 
and sex (Beta = 0.502, p < 0.001, R2 = 0.278), for 
age, sex and HOMA-IR (Beta = 0.307, p = 0.002, 
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R2 = 0.336), for age, sex and hsCRP (Beta = 0.474, 
p < 0.001, R2 = 0.281), for age, sex and HDL-C 
(Beta = 0.493, p < 0.001, R2 = 0.279), as well as after 
the adjustment for age, sex, and SBP (Beta = 0.437, 
p < 0.001, R2 = 0.293).
All variables found to have a significant predictive 
value in the linear regression model (e.g.,  WC, 
HOMA-IR, HDL-C, hsCRP, SBP, and eGFR), 
were further analyzed in multiple linear regression 
analysis for cystatin C prediction. In multiple linear 
regression analysis, WC (Beta = 0.376; p < 0.001) 
and eGFR (Beta = -0.484; p < 0.001) remained sig-
nificant independent predictors of serum cystatin C 
level among all participants (R2 = 0.447; p < 0.001) 
(Table 4).
DISCUSSION
When initially mentioned, serum cystatin C was 
assumed to be related only to renal pathology (1). 
In the current study, obese (otherwise healthy par-
ticipants) displayed significantly higher cystatin C 
levels as compared with normal-weight participants. 
These findings are in accordance with the results 
reported by Naour et al. (3,4), who also found 
higher serum cystatin C levels in obese versus nor-
mal-weight counterparts. Moreover, they reported 
that cystatin C was highly expressed in human adi-
pose tissue, equally in subcutaneous and omental 
fat depots (3), suggesting that cystatin C may play 
a role in preventing inflammation and controlling 
adipose tissue mass through cathepsins inhibition.
The observed association between serum cystatin C 
levels and anthropometric indices (e.g.,  BMI and 
WC) was also shown by some previous reports (5-7). 
However, in the current study the association 
between WC and cystatin C was stronger than 
reported for BMI and cystatin C, indicating that 
visceral, rather than overall adiposity, is more closely 
related to higher cystatin C levels (5). This associa-
tion between cystatin C and WC remained signifi-
cant even after the adjustment for confounding fac-
tors. On the other hand, some other studies (10-15) 
failed to find the association between cystatin C 
and obesity-related parameters, thus rejecting the 
TABLE 1. General characteristics of studied participants
Characteristics Normal‑weight (n=53) Obese (n=79) p
Age (years) 56.1±6.57 56.3±6.88 0.823
Sex (females) % (n) 66.0 (35) 69.6 (55) 0.807
BMI (kg/m²) 23.0±1.43 30.1±3.10 <0.001
WC (cm) 81.5±7.43 101.5±9.99 <0.001
Fasting glucose (mmol/L) 5.34±0.36 5.52±0.40 0.006
Fasting insulin (µIU/L) 4.10 (3.10‑5.92) 9.24 (5.85‑15.85) <0.001
HOMA‑IR 0.99 (0.73‑1.50) 2.34 (1.45‑4.04) <0.001
TC (mmol/L) 6.09±1.43 6.14±1.12 0.845
HDL‑C (mmol/L) 1.67±0.46 1.39±0.45 <0.001
LDL‑C (mmol/L) 3.95±1.41 4.05±1.19 0.649
TG (mmol/L) 1.21 (1.00‑1.46) 1.51 (1.02‑2.28) 0.015
SBP (mm Hg) 128±14.9 141±15.0 <0.001
DBP (mm Hg) 79.3±9.62 89.5±9.68 <0.001
hsCRP (mg/L) 0.55 (0.24‑1.22) 1.65 (1.00‑3.21) <0.001
Creatinine (µmol/L) 61.9±13.76 65.1±13.45 0.190
eGFR (mL/min/1.73 m²) 98.1±11.08 95.3±11.14 0.156
UAE (mg/24 h) 5.92 (4.96‑7.90) 6.65 (4.99‑8.90) 0.257
Cystatin C (mg/L) 0.75 (0.68‑0.80) 0.81 (0.73‑0.87) <0.001
Data are presented as mean±standard deviation or median (interquartile range), or counts and percentages, BMI: Body mass index, 
WC: Waist circumference, HOMA‑IR: Homeostasis model assessment of insulin resistance, TC: Total cholesterol, HDL‑C: High density 
lipoprotein cholesterol, LDL‑C: Low density lipoprotein cholesterol, TG: Triglycerides, SBP: Systolic blood pressure, DBP: Diastolic 
blood pressure, hsCRP: High sensitivity C reactive protein, eGFR: Estimated glomerular filtration rate, UAE: Urinary albumin excretion
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hypothesis that body composition affects cystatin C 
levels.
Sledziński et al. (19) also reported significantly 
higher serum cystatin C concentrations in obese 
patients compared to non-obese subjects. However, 
decrease of body and fat mass after bariatric sur-
gery resulted in improvement of cardiometabolic 
parameters (e.g.,  serum lipids, blood pressure, and 
insulin sensitivity), but surprisingly the mean post-
operative serum cystatin C concentration was not 
significantly different from that before the surgery, 
suggesting that serum cystatin C concentration is 
not tightly associated with body and fat mass loss 
in obese patients.
Obesity is an independent risk factor for renal 
impairment, as showed by Chen et al. (20) who 
reported that the risk for CKD was more than 
twice as high in patients with increased WC than in 
those without increased WC. Furthermore, Young 
et al. (21) found that visceral and subcutaneous adi-
pose tissue (as measured by computed tomography) 
were associated with CKD defined only with cysta-
tin C estimating equations, but not when using a 
creatinine-based estimating equations.
Obesity is an independent risk factor for kid-
ney dysfunction, even in pediatric age groups (9). 
Furthermore, Codoñer-Franch et al. (9) showed 
that obese children at the highest tertile of cystatin 
C levels had the cluster of several cardiometabolic 
risk factors, and cystatin C levels were correlated 
with cardiometabolic risk factors independently of 
renal function.
In our study, serum cystatin C correlated with 
blood pressure, both SBP and DBP, which is similar 
to other findings (8). Namely, Salgado et al. (22) 
reported the association of SBP, but not DBP, with 
serum cystatin C levels. On the other hand, Mena 
et  al. (23) found that DBP negatively correlated 
TABLE 2. Correlations of serum cystatin C level and studied 
parameters in all participants
Variable r p
Age (years) 0.201 0.021
BMI (kg/m²) 0.330 <0.001
WC (cm) 0.472 <0.001
Glucose (mmol/L) 0.270 0.002
Fasting insulin (µIU/L) 0.439 <0.001
HOMA‑IR 0.447 <0.001
TC (mmol/L) 0.052 NS
HDL‑C (mmol/L) ‑0.185 0.034
LDL‑C (mmol/L) 0.094 NS
TG (mmol/L) 0.192 0.028
SBP (mm Hg) 0.378 <0.001
DBP (mm Hg) 0.362 <0.001
hsCRP (mg/L) 0.320 <0.001




UAE (mg/24 h) 0.121 NS
BMI: Body mass index; WC: Waist circumference, 
HOMA‑IR: Homeostasis model assessment of insulin 
resistance, TC: Total cholesterol, HDL‑C: High density 
lipoprotein cholesterol, LDL‑C: Low density lipoprotein 
cholesterol, TG: Triglycerides, SBP: Systolic blood pressure, 
DBP: Diastolic blood pressure, hsCRP: High sensitivity 
C‑reactive protein, eGFR: Estimated glomerular filtration rate, 
UAE: Urinary albumin excretion, NS: Nonsignificant
TABLE 3. Linear regression models with association between cystatin C and WC, and association between cystatin C and 
eGFR, independently in all participants
WC eGFR
R2 Std Beta p R2 Std Beta p 
No adjustment 0.222 0.472 <0.001 0.311 ‑0.558 <0.001
Age, sex* 0.278 0.502 <0.001 0.319 ‑0.558 <0.001
Age, sex, HOMA‑IR* 0.336 0.307 0.002 0.449 ‑0.460 <0.001
Age, sex, hsCRP* 0.281 0.474 <0.001 0.371 ‑0.539 <0.001
Age, sex, HDL‑C* 0.279 0.493 <0.001 0.340 ‑0.541 <0.001
Age, sex, SBP* 0.293 0.437 <0.001 0.383 ‑0.521 <0.001
*After adjustment, WC: Waist circumference, eGFR: Estimated glomerular filtration rate, HOMA‑IR: Homeostasis model assessment 
of insulin resistance, hsCRP: High sensitivity C‑reactive protein, HDL‑C: High density lipoprotein cholesterol, SBP: Systolic blood 
pressure
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with cystatin C, while Shankar et al. (24) confirmed 
that mild reductions in kidney function as measured 
by serum cystatin C levels among subjects without 
clinically recognized chronic kidney disease were 
associated with hypertension in women, but not in 
men.
Previous studies have also shown that higher cysta-
tin C levels were closely related to insulin resistance 
and inflammation (8,25). Although we observed 
significant association of cystatin C with inflamma-
tion (as measured by hsCRP), dyslipidemia, insulin 
resistance and hypertension in all participants, these 
associations were rejected after the multiple linear 
regression analysis, while only the association with 
WC and eGFR remained significant. Adipose tis-
sue dysfunction has been shown to be a mediator 
in the development of obesity-associated complica-
tions (26). The results of the current study suggest 
that the relationship between serum cystatin C and 
inflammation, insulin resistance, endothelial dys-
function and activation of the renin-angiotensin-al-
dosterone system, all of which may be interrelated, 
could be secondary to the underlying association 
between serum cystatin C and obesity.
Despite the fact that we did not measure GFR 
directly and despite the cross-sectional nature of 
this study which makes the interpretation of the 
results limited, it is important to emphasize that 
we included only participants who were not under 
any medicament therapy which might influence the 
associations between cystatin C and other variables. 
Moreover, we excluded participants with eGFR < 
60 mL/min/1.73 m2 and albuminuria, CVD, DM, 
thyroid dysfunction, and acute inflammation and 
smoking, all of which may be strong determinants 
of cystatin C. As our study was not based on general 
population, selection bias might have affected the 
outcome of the study. The current study, however, 
suggests that serum cystatin C level can be used as a 
potential indicator of obesity and metabolic abnor-
malities associated with obesity, independent of 
renal function.
CONCLUSION
Cystatin C is independently associated with abdom-
inal obesity and its relationship with changes in 
other target organs should be evaluated.
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